Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Natural products have always been exploited to promote health and served as a valuable source for the discovery of new drugs. In this review, the great potential of natural compounds and medicinal plants for the treatment or prevention of cardiovascular and metabolic disorders, global health problems with rising prevalence, is addressed. Special emphasis is laid on natural products for which efficacy and safety have already been proven and which are in clinical trials, as well as on plants used in traditional medicine. Potential benefits from certain dietary habits and dietary constituents, as well as common molecular targets of natural products, are also briefly discussed. A glimpse at the history of statins and biguanides, two prominent representatives of natural products (or their derivatives) in the fight against metabolic disease, is also included. The present review aims to serve as an “opening” of this special issue of Molecules, presenting key historical developments, recent advances, and future perspectives outlining the potential of natural products for prevention or therapy of cardiovascular and metabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257 · cited 1×
“), minimal food processing, olive oil, and wine consumed in low to moderate amounts, normally with meals [19,182,183].”
RetractedEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1806491 · Cited by 1,008
RetractedMozaffarian, D. (2016) · Circulation · doi:10.1161/circulationaha.115.018585 · Cited by 2,216 · cited 1×
“Ample evidence demonstrates that dietary patterns can affect the development of cardiovascular and metabolic disorders [179,180].”
Barone, J. J., & Roberts, H. R. (1996) · Food and Chemical Toxicology · doi:10.1016/0278-6915(95)00093-3 · Cited by 705
Ding, M., Bhupathiraju, S. N., Satija, A., van Dam, R. M., & Hu, F. B. (2014) · Circulation · doi:10.1161/circulationaha.113.005925 · Cited by 565
AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458
The CardioMetabolic Health Alliance
Sperling, L. S., Mechanick, J. I., Neeland, I. J., Herrick, C. J., Després, J.-P., Ndumele, C. E., Vijayaraghavan, K., Handelsman, Y., Puckrein, G. A., Araneta, M. R. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1328 · Cited by 294 · cited 1×
“The metabolic syndrome is considered to be a progressive pathophysiological state which is clinically manifested by a cluster of interrelated risk factors (abdominal obesity, atherogenic dyslipidemia, increased blood pressure, insulin resistance, pro-inflammatory and prothrombotic state) and associated with an increas…”
van Dijk, A. E., Olthof, M. R., Meeuse, J. C., Seebus, E., Heine, R. J., & van Dam, R. M. (2009) · Diabetes Care · doi:10.2337/dc09-0207 · Cited by 293
Protective role of epigallocatechin-3-gallate in health and disease: A perspective
Chowdhury, A., Sarkar, J., Chakraborti, T., Pramanik, P. K., & Chakraborti, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.013 · Cited by 164 · cited 6×
“The effects of EGCG (Figure 3) are multifaceted and include among others the inhibition of the activator protein 1 (AP-1), the nuclear factor kappa B (NF-κB), the tumor necrosis factor α (TNFα) signaling, the inhibition of the vascular endothelial growth factor (VEGF) signaling, the insulin-like growth factor (IGF-1)…”
InfluentialSobenin, I. A., Nedosugova, L. V., Filatova, L. V., Balabolkin, M. I., Gorchakova, T. V., & Orekhov, A. N. (2008) · Acta Diabetologica · doi:10.1007/s00592-007-0011-x · Cited by 119
Beejmohun, V., Peytavy-Izard, M., Mignon, C., Muscente-Paque, D., Deplanque, X., Ripoll, C., & Chapal, N. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-351 · Cited by 97
Whitfield, P., Parry-Strong, A., Walsh, E., Weatherall, M., & Krebs, J. D. (2016) · European Journal of Nutrition · doi:10.1007/s00394-015-0926-x · Cited by 51
Di Pierro, F., Bellone, I., Rapacioli, G., & Putignano, P. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s78877 · Cited by 48
Cited by
Natural products in drug discovery: advances and opportunities
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Taskforce, T. I. N. P. S., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00114-z · Cited by 5,392
Self-citationAltobelli, E., Angeletti, P. M., Marziliano, C., Mastrodomenico, M., Giuliani, A. R., & Petrocelli, R. (2021) · Nutrients · doi:10.3390/nu13020404 · Cited by 67
Huang, Y., Chen, K., Ren, Q., Yi, L., Zhu, J., Zhang, Q., & Mi, M. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493040 · Cited by 64
Metadata
- Authors
- Waltenberger, B., Mocan, A., Šmejkal, K., Heiss, E., & Atanasov, A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2016-06-22
- Volume
- 21
- Issue
- 6
- Pages
- 807
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2473126528
- Cited by
- 175
- References
- 13
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.